AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

Friday, December 9, 2022
Webinar -- 3:30 PM CT
https://www.clinicaloptions.com/AmyloidosisHEME2022Join1

Agenda

Welcome and Introduction

Real-world Cases and Panel Discussion

  • Biology, clinical presentation, and diagnostic approach for AL amyloidosis
  • Current/evolving management algorithm for the patient with newly diagnosed AL amyloidosis
  • Treatment response assessment; hematologic/organ response criteria
  • Current/evolving algorithm for the management of AL amyloidosis at relapse
  • Supportive management in AL amyloidosis
  • Common pitfalls in the management of patients with AL amyloidosis

Future Directions

Audience Question and Answer Session

Faculty

Program Director
Angela Dispenzieri, MD

Serene and Francis During Named Professor
Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, Minnesota

Faculty
Anita D’Souza, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Medical College of Wisconsin
Attending Physician
Froedtert & Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

Faculty
Jeffrey Zonder, MD

Professor of Oncology  
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in using novel therapeutic options for patients with AL amyloidosis.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Diagnose AL amyloidosis through timely and accurate typing of the precursor protein to guide specific management approaches
  • Integrate into practice up-to-date efficacy and safety data on currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
  • Plan evidence-based supportive therapy in AL amyloidosis to improve quality of life, relieve symptoms, and sustain organ function
  • Identify patients appropriate for enrollment on ongoing clinical trials evaluating novel therapy for the treatment of patients with AL amyloidosis

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.